GUNA-TF
The Homeopathic Use of Transfer factors

Physiological Therapy in chronic and recurrent infections
**WHAT ARE GUNA-TF?**

**GUNA-TF** are Transfer Factors protein-based innovative homeopathic medicines at D7 (7X for US Physicians) potency ($10^{-7}$).

The Transfer Factors are therapeutically active at a dosage of 100 ng/day; to obtain this specific concentration (corresponding to the amount of Transfer Factors that are contained in a Guna-TF capsule), the technique of homeopathic preparation has been used in order to realize a standard production according to current Good Manufacturing Practice.

Transfer factors are short ribonucleopeptide chains with antigenic messenger RNA bases connected with short peptide chains composed of 6 or more amino acids. In simple words, they are tiny molecules providing for immune defence. They are all natural substances that work by “teaching” our own immune system to identify infectious agents that attack our body every day.

Guna-TF are manufactured through a patented procedure by extracting them from lymph cells activated by specific antigens (viruses, yeasts, etc.). These lymphoid lines are being cultivated in vitro and dialysed: in this way, the so-called DLE (Dialyzable Leukocyte Extract) can be containing over 200 molecules, weighting between 1,000 and 20,000 Dalton. Among these, there are Transfer Factors proteins responsible for the **transfer of cell-mediated immunity**.
One of the most common theories on the mechanism of action of Transfer Factors is that they are part of the receptor lying on the Th lymphocyte surface in a steric position that is necessary to identify the specific antigenic agent.

Administering Transfer Factors proteins means activating the mechanisms of receptor re-synthesis (specific receptors of a specific antigen) by Th lymphocytes, thus enhancing their receptor capacity and hence their immune effectiveness. Transfer Factors are also capable of activating intracellular mechanisms responsible for the production of cytokines, which are important intracellular communication messengers between different immune response intermediates. In particular, they activate the synthesis of pro-inflammatory interleukins (for instance IL1, IL6, TNF, INF, etc) which are essential to induce an effective physiological response towards a pathogen agent.
The chronicization and recurrence of an infectious disease represent the most evident sign that the Immune System has been attacked by pathogen agents.

Transfer Factors struggle against the body non-response by providing it with the necessary factors to help the Immune System face the antigen attack.

Guna-TF treatment is capable of transferring the immune pathway of the donor of Transfer Factors to the patient to be treated to trigger an autologous response that has to be sufficient and suitable to fight the antigenic attack in a physiological way.

The treatment with Guna-TF is suitable in the forms of cell-mediated immune selected deficit.

The response is specific only toward the antigen codifying the Transfer Factor:

- Herpes simplex type 1 and 2
- Monilia albicans
- HPV
- Guna-TF Herpes
- Guna-TF Candida
- Guna-TF Papilloma
100 ng/die = quantity of Transfer Factors proteins that are therapeutically active and correspond to the quantity of TF D7 (7 x for US Physicians) in a capsule of Guna-TF

Transfactor = Transfer of cell-mediated immunity

Transfactor = Antigen-specific immunotherapy

Transfactor = Physiological treatment of chronic recurrent infections diseases

Transfactor = Effective and risk-free treatment

**HOW TO USE GUNA-TF:**

- Guna-TF are in capsules for oral use.
- Standard dosage: 1 capsule/day for 5 continuous days (for instance: from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

**PACKAGE SIZE**

Bottle of 20 x 230 mg capsules.
**Composition**
Transfer Factors-HSV type 1 and 2 at D7 potency (7X for US Physicians).

**Indications**
Herpes labialis and Herpes genitalis recurrent infections; herpetic keratoconjunctivitis; herpetic-like cutaneous infections.

**Dosage**
1 capsule/day for 5 continuous days (for instance: from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

**Package size**
Bottle of 20 x 230 mg capsules.

**Combination with other Guna medicines:**
- **Strengthening of immune defenses in Herpes simplex I and II infections:**
  Guna-TF Herpes + Guna-Virus
A clinical research study has been carried out on 44 patients, 22 affected by labial herpes and 22 affected by genital herpes. All the patients have been treated for 6 continuous months with a Transfer Factor preparation obtained from in vitro culture extract of specific HSV 1 and 2 from dialyzed bovine lymphocytes.

In the monitoring period before the treatment (the 44 patients have been monitored globally 26,660 days long) there have been 544 reacutizations with a 61.2 Relapse Index.

The monitoring period during and after treatment has been of 16,945 days for the 44 patients. In this period there have been 121 reacutizations with a 21.4 Relapse Index.

Composition
Transfer Factor Monilia albicans at D7 potency (7X for US Physicians).

Indications
Recurrent Candida infections; mucocutaneous yeast problems in different body areas; dermatitis.

Dosage
1 capsule/day for 5 continuous days (for instance from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.

Package size
Bottle of 20 x 230 mg capsules.

Combination with other Guna medicines:
- Acute and chronic Vulvo-vaginites as a consequence of yeast problems (Candidiasis):
  Guna-TF Candida + Mycox™ + Citomix™ (20 drops three times/day for 1 month)
- Dysbiotic Candidiasis: Guna-TF Candida + Eubioflor™ + Citomix™
  (20 drops three times/day for 2 months)
Guna-TF-Candida in chronic mucocutaneous Candidiasis

A clinical research study has been carried out on 15 patients (3 M; 12 F) affected by Chronic Mucocutaneous Candidiasis (6 patients with oral Candidiasis and 9 patients with Vaginal Candidiasis).

The patients have been treated with a Transfer Factor preparation from in vitro culture extract of Monilia albicans. The CMI (Cell-Mediated Immunity) has been considered through the Leukocyte Migration Test (LMT) and the Lymphocyte Stimulation Test (LST) with the presence of Candidiasis lysate before, during and after treatment. 83.9% of LMTS Test were positive during treatment, showing an increased incidence of Candidiasis antigen reactivity.

In the monitoring period improvements of the health condition have been recorded.

**GUNA-TF PAPILLOMA**

<table>
<thead>
<tr>
<th>Composition</th>
<th>Transfer Factor Papillomavirus at D7(7 X for US Physicians) potency.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indications</td>
<td>Recurrent Papillomavirus infections; condylomatoses; post-surgical condyloma treatment; warts.</td>
</tr>
<tr>
<td>Dosage</td>
<td>1 capsule/day for 5 continuous days (for instance from Monday to Friday, excluding Saturday and Sunday) for 3-4 months without break.</td>
</tr>
<tr>
<td>Package size</td>
<td>Bottle of 20 x 230 mg capsules.</td>
</tr>
</tbody>
</table>

**Combination with other Guna medicines:**
- Strengthening of immune defenses in Human Papilloma Virus (HPV) infections: Guna-TF Papilloma + Citomix™
A clinical research study has been carried out on 160 patients, both male and female, affected by HPV (Papilomavirus) lesions or PAP test or biopsy positive to koilocytosis to consider the results of a treatment with Transfer Factor preparation from in vitro culture HPV extract to prevent relapses. The protocol provided for the use of one capsule/day for 5 continuous days/week for 8 weeks and then one capsule/day for 3 days/week (on alternate days) for another 4 weeks. The viral HPV lesions have almost disappeared in the patients treated.

In 97% of the cases where the electrosurgical treatment has been used in conjunction with the preparation no further persistent symptoms of disease have been recorded.

From M. Destro Castaniti. “L’utilizzo del Tranfator 11 nella patologia virale da HPV (casistica di 160 casi)”. La Medicina Biologica, 2000/4, 95-100.


27. Orlandini A. - Il Transfer Factor: la proteina responsabile del trasferimento della reattività cellulare mediata verso antigeni specifici - La Medicina Biologica 1996/2; pagg. 37-42.
35. Viza D. - Transfer Factor: un immunomodulatore nella lotta contro le malattie infettive -
La Medicina Biologica 2000/4, pagg. 31-37.


Contact Us

For USA customers
GUNA Incorporated
1520 Tramway Blvd. NE, STE, 150
Albuquerque, New Mexico 87112, USA
1-888-GUNA-TEL (486-2835)
1-888-GUNA-FAX (486-2329)
Contact your Medical Sales Consultant directly at: 505-217-3977
or fax to 505-217-3996
Please give us your opinion and feedback by emailing us at info@gunainc.com

For all other countries outside the United States
Please email us at export@guna.it